Brokers Set Expectations for Pfizer's Q3 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Analysts at Leerink Partnrs cut their Q3 2025 EPS estimates for shares of Pfizer in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $1.10 per share for the quarter, down from their prior forecast of $1.11. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer's FY2029 earnings at $2.36 EPS.

A number of other research analysts also recently commented on the stock. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Trading Down 1.3 %

Shares of PFE stock traded down $0.34 during mid-day trading on Friday, hitting $25.53. 36,520,039 shares of the company's stock were exchanged, compared to its average volume of 38,701,305. The stock has a market cap of $144.69 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 0.64 and a beta of 0.64. The stock has a 50-day simple moving average of $26.28 and a two-hundred day simple moving average of $27.69. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 EPS. The firm's revenue for the quarter was up 24.7% on a year-over-year basis.

Institutional Trading of Pfizer

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares in the last quarter. State Street Corp raised its position in shares of Pfizer by 1.2% in the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after purchasing an additional 3,405,539 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the period. Geode Capital Management LLC grew its stake in Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after buying an additional 1,855,419 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.74%. Pfizer's payout ratio is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.